RVMD Q3 earnings and sales beat estimates on Rasonque uptake
FROM THE WIRE · FINANCE.YAHOO.COM
Revolution Medicines RVMD reported a loss of $1.90 per share in the third quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of $2.34. However, the loss widened 18% from $1.61 per share a year ago. Revenues of $197.6 million beat the Zacks Consensus Estimate…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe mid-cap biotech shares rose after a quarter better than expected.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Revolution Medicines reported a loss of $1.90 per share in Q3 2026.
- 02Revenues of $197.6 million beat estimates.
- 03Shares rose 6% in after-hours trading.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets